Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
Edward Wolin
Consultant or Advisory Role - Novartis
Nicola Fazio
Honoraria - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Robert Winkler
Employment or Leadership Position - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Larry Kvols
Consultant or Advisory Role - Novartis
Honoraria - Novartis